The maintenance of an Outperform rating by RBC Capital suggests a positive outlook on ACADIA Pharmaceuticals, indicating confidence in the company's future performance. However, the reduction in the price target from $36 to $35, although minor, could imply a slight adjustment in expectations regarding the company's near-term growth prospects or market conditions. This adjustment is likely based on recent data or market trends analyzed by the analyst. The overall impact on the stock price is neutral in the short term as the positive sentiment from maintaining the Outperform rating could be slightly offset by the lowered price target.